This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
Safety and Biomarker Responses of Delgocitinib (JAK1,2,3/TYK2 Inhibitor) in Central Centrifugal Cicatricial Alopecia and Lichen Planopilaris | MicrobiomeTrials
← Back to trials NCT07487948
Safety and Biomarker Responses of Delgocitinib (JAK1,2,3/TYK2 Inhibitor) in Central Centrifugal Cicatricial Alopecia and Lichen Planopilaris Recruiting PHASE2 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2026-05-19Est. Completion: 2027-04-05
Enrollment target: 30 participantsLocations Icahn School of Medicine at Mount Sinai, New York, New York, United States Other microbiome trials you might be interested in Cicatricial Alopecia
Alopecia could be subdivided into two main groups of diseases: non-scarring alopecia, such as male pattern baldness, or …
New York, United States Completed Mar 20, 2025
Central Centrifugal Cicatricial Alopecia Frontal Fibrosing Alopecia
This is a prospective, open-label clinical trial, in which all participants will be treated with deucravacitinib for 48 …
New York, United States Est. completion Jun 30, 2028